uniQure (NASDAQ:QURE) Price Target Lowered to $35.00 at Chardan Capital

Key Points

• Chardan Capital has lowered its price target for uniQure from $38.00 to $35.00, suggesting a potential upside of 155.85% from the stock's current price.
• While Chardan maintains a "buy" rating, other analysts have issued mixed opinions, with one downgrading the stock and others varying between "hold," "buy," and "strong buy" ratings.
• uniQure's shares have seen a significant decline of 8.7%, trading at $13.68, and the company reported a negative earnings result of ($0.82) EPS, surpassing estimates but indicating ongoing challenges.

uniQure (NASDAQ:QURE - Get Free Report) had its target price dropped by analysts at Chardan Capital from $38.00 to $35.00 in a note issued to investors on Tuesday, MarketBeat reports. The firm presently has a "buy" rating on the biotechnology company's stock. Chardan Capital's price objective indicates a potential upside of 149.11% from the company's current price.

QURE has been the subject of a number of other reports. Cantor Fitzgerald upgraded uniQure to a "strong-buy" rating in a research report on Monday, May 19th. HC Wainwright restated a "buy" rating and set a $70.00 price objective on shares of uniQure in a research report on Thursday, May 29th. Guggenheim reiterated a "buy" rating and issued a $28.00 target price on shares of uniQure in a report on Monday, May 12th. Finally, Wall Street Zen downgraded uniQure from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, uniQure presently has a consensus rating of "Moderate Buy" and a consensus price target of $36.55.

uniQure Trading Down 2.8%

Shares of NASDAQ:QURE traded down $0.41 during mid-day trading on Tuesday, reaching $14.05. 467,874 shares of the company's stock were exchanged, compared to its average volume of 1,424,023. The firm has a market capitalization of $769.60 million, a price-to-earnings ratio of -3.59 and a beta of 0.08. The business's fifty day moving average price is $14.89 and its 200-day moving average price is $13.68. The company has a debt-to-equity ratio of 1.53, a quick ratio of 11.99 and a current ratio of 9.98. uniQure has a twelve month low of $4.45 and a twelve month high of $19.18.

uniQure (NASDAQ:QURE - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.89) by $0.20. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%. The company had revenue of $5.26 million during the quarter, compared to the consensus estimate of $5.00 million. On average, research analysts predict that uniQure will post -3.75 EPS for the current fiscal year.

Insider Activity at uniQure

In related news, Director Madhavan Balachandran sold 2,112 shares of the business's stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $14.45, for a total transaction of $30,518.40. Following the transaction, the director directly owned 37,697 shares in the company, valued at approximately $544,721.65. The trade was a 5.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Robert Gut sold 3,336 shares of the business's stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $14.45, for a total transaction of $48,205.20. Following the transaction, the director owned 56,879 shares in the company, valued at approximately $821,901.55. This trade represents a 5.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 22,144 shares of company stock valued at $322,426 over the last 90 days. Corporate insiders own 4.79% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in QURE. Raymond James Financial Inc. bought a new position in shares of uniQure during the 4th quarter worth $1,951,000. JPMorgan Chase & Co. raised its position in shares of uniQure by 14.7% in the fourth quarter. JPMorgan Chase & Co. now owns 453,784 shares of the biotechnology company's stock valued at $8,014,000 after purchasing an additional 58,246 shares during the period. Alliancebernstein L.P. raised its position in shares of uniQure by 14.2% in the fourth quarter. Alliancebernstein L.P. now owns 203,919 shares of the biotechnology company's stock valued at $3,601,000 after purchasing an additional 25,319 shares during the period. Franklin Resources Inc. lifted its position in shares of uniQure by 33.1% during the fourth quarter. Franklin Resources Inc. now owns 1,987,688 shares of the biotechnology company's stock worth $35,103,000 after acquiring an additional 494,726 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new stake in shares of uniQure during the fourth quarter worth $326,000. Institutional investors own 78.83% of the company's stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.